Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 05 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2017.
- 05 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2014 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 according to ClinicalTrials.gov record.